Edesa Biotech (EDSA) Common Equity (2013 - 2026)
Edesa Biotech (EDSA) posted Common Equity of $14.0 million for Q4 2025, up 12.06% sequentially from $12.5 million in Q3 2025, and up 516.37% YoY from $2.3 million in Q4 2024.
Edesa Biotech (EDSA) Common Equity (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Common Equity for 13 years, with the latest figure at $14.0 million in Q4 2025.
- Quarterly Common Equity rose 516.37% year-over-year to $14.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.0 million (up 516.37% YoY) and the FY2025 annual result came in at $12.5 million, up 528.52% from the prior year.
- Common Equity rose to $14.0 million in Q4 2025 per EDSA's latest filing, from $12.5 million in the prior quarter.
- Over five years, Common Equity peaked at $19.3 million in Q1 2021 and troughed at $2.0 million in Q3 2024.
- A 5-year average of $10.2 million and a median of $10.4 million in 2021 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 71.89% in 2024, then surged 528.52% in 2025.
- Over 5 years, Common Equity stood at $10.5 million in 2021, then retreated by 2.61% to $10.3 million in 2022, then tumbled by 43.11% to $5.8 million in 2023, then sank by 61.27% to $2.3 million in 2024, then jumped by 516.37% to $14.0 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $14.0 million, $12.5 million, and $14.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 9.79 Bn |
| 10 | Edesa Biotech | 44.32 Mn | 44.32 Mn | - | 8.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.81 Mn |
| Dec 31, 2025 | 13.95 Mn |
| Sep 30, 2025 | 12.45 Mn |
| Jun 30, 2025 | 14.13 Mn |
| Mar 31, 2025 | 15.54 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 2.87 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 5.84 Mn |
| Sep 30, 2023 | 7.05 Mn |
| Jun 30, 2023 | 7.85 Mn |
| Mar 31, 2023 | 9.00 Mn |
| Dec 31, 2022 | 10.27 Mn |
| Sep 30, 2022 | 9.39 Mn |
| Jun 30, 2022 | 11.84 Mn |
| Mar 31, 2022 | 17.02 Mn |
| Dec 31, 2021 | 10.55 Mn |
| Sep 30, 2021 | 13.06 Mn |
| Jun 30, 2021 | 15.80 Mn |